리포트 개요
패혈증 진단 세계 시장은 2023년에 7억 1,013만 달러에 달하며, 2031년에는 14억 3,524만 달러에 달할 것으로 예측되며, 예측 기간인 2024-2031년 CAGR은 9.5%로 성장할 전망입니다.
패혈증은 신체의 면역체계가 감염에 과도하게 반응하여 장기의 기능 장애를 일으키는 생명을 위협하는 질병입니다. 신체 반응은 조직과 장기에 손상을 입히고, 신속하게 발견하고 치료하지 않으면 쇼크, 다발성 장기부전, 심지어 사망에 달할 수도 있습니다.
혈액 검사, 소변, 상처에서 나오는 액체, 점액, 기도에서 나오는 타액 등 기타 검사 항목을 통해 이 병을 진단할 수 있습니다.
촉진요인과 억제요인
감염병 부담 증가
감염병을 빨리 발견하고 치료하지 않으면 패혈증과 같은 심각한 질환으로 발전할 수 있습니다. 따라서 패혈증으로 발전할 수 있는 감염을 조기에 진단하는 것이 중요합니다. 패혈증 진단 검사는 의료진이 병을 조기에 발견하고 적절한 개입과 관리를 할 수 있도록 도와주며, HAI는 병원내 감염으로 패혈증의 주요 원인입니다.
의료 관련 감염이 지속적으로 증가함에 따라 이러한 환경에서 환자를 모니터링하고 패혈증을 조기에 진단할 수 있는 정확한 진단 툴의 필요성이 증가하고 있습니다.
유럽에서 가장 빈번한 6가지 HAI의 부담은 신체적 장애와 조기 사망 측면에서 다른 32개 감염성 질환의 전체 부담의 두 배에 달하는 것으로 계산되었습니다.
또한 2023년 Balasubramanian 등이 발표한 연구에 따르면 전 세계에서 매년 약 1억 3600만 건의 의료 관련 항생제 내성 감염이 발생하고 있습니다. 이러한 감염 부담 증가는 시장 성장의 원동력이 될 것으로 예상됩니다.
진단 툴의 높은 비용
자동 진단 기기나 바이오마커 검사는 고가의 비용이 발생할 수 있습니다. 초기 비용이 높으면 의료기관의 전반적인 도입률이 낮아질 수 있습니다. 이는 패혈증 진단 시장의 성장 둔화와 직결됩니다. 이러한 제약에도 불구하고 병원들은 더 저렴한 기존 방법을 계속 사용할 것으로 보입니다.
Report Overview
The Global Sepsis Diagnostics Market reached US$ 710.13 million in 2023 and is expected to reach US$ 1,435.24 million by 2031, growing at a CAGR of 9.5% during the forecast period 2024-2031.
Sepsis is a life-threatening illness that occurs when the body's immune system overreacts to an infection, causing organ malfunction. The body's response damages its tissues and organs, which can result in shock, multiple organ failure, and even death if not detected and treated swiftly.
Blood tests and other lab tests such as urine, liquid from the wound, mucus, and saliva from the respiratory tract are performed to diagnose the condition.
Market Dynamics: Drivers & Restraints
The growing burden of infectious diseases
If infectious infections are not detected and treated promptly, they can develop into serious conditions such as sepsis. As a result, there is a greater emphasis on early diagnosis of infections that could develop into sepsis. Diagnostic tests for sepsis assist healthcare providers in detecting the condition early, allowing for appropriate intervention and management. HAIs are hospital-acquired infections that can significantly contribute to sepsis cases.
As healthcare-associated infections continue to rise, there is a greater need for precise diagnostic tools to monitor patients and diagnose sepsis early in these settings.
In Europe, the burden of the six most frequent HAIs was calculated to be twice the burden of 32 other infectious diseases altogether, in terms of disability and premature mortality.
Additionally, according to research published by 2023 Balasubramanian et al., an estimated 136 million cases of healthcare-associated antibiotic-resistant infections occur worldwide every year. Thus, the increasing burden of infectious diseases is expected to drive the market growth.
High Cost of Diagnostic Tools
Automated diagnostic instruments and biomarker tests can be costly. High upfront expenses could result in a slower overall adoption rate among medical facilities. This directly translates into slower growth in the sepsis diagnostics market. Despite these limitations, hospitals will continue to use older, less expensive methods.
The global sepsis diagnostic market is segmented based on product, technology, diagnostic method, pathogen, end-user and region.
Blood Culture Media segment is expected to dominate the market growth
Blood culture media is expected to be the dominant segment in the sepsis diagnostics market. Blood culture media is a less expensive diagnostic technique than other approaches such as molecular diagnostics. Blood culture media is readily accessible and simple in most therapeutic settings.
While more rapid approaches are emerging, blood cultures remain the accepted standard for identifying the specific pathogens causing sepsis since they allow for the growth and identification of bacteria or fungi. Thus, the above factors are expected to hold the segment in the dominant position.
North America is expected to hold a significant position in the sepsis diagnostic market share
North America is expected to dominate the sepsis diagnostic market owing to the increasing prevalence of sepsis and the technological advancements in sepsis diagnosis such as advanced diagnostic facilities and high adoption rates of medical technologies are expected to drive the market growth in the region. The medical diagnostic companies in the region are introducing several tests and the required sepsis diagnostic tools which could help in driving the market growth.
Foe instance, in August 2023, Medical diagnostic company Cytovale commercially introduced its new diagnostic tool, the IntelliSep sepsis test, in the US. The test was launched following 510(k) clearance from the US Food and Drug Administration in December 2022.
Additionally, on April 3, 2024, Prenosis, Inc. received the U.S. Food and Drug Administration (FDA) approval of the marketing authorization for the Sepsis ImmunoScoreTM using the De Novo pathway. The Sepsis ImmunoScoreTM is an artificial intelligence/machine learning software as a medical device (AI SaMD) to guide rapid diagnosis and prediction of sepsis. Thus, the above factors are expected to hold the region in the dominant position.
Instruments
Software
Blood Culture Media
Assays & Reagents
Others
Flow Cytometry
Microbiology
Biomarkers
Molecular Diagnostics
Microfluidics
Others
Automated Diagnostics
Conventional Diagnostics
Fungal Sepsis
Bacterial Sepsis
Gram-Positive Bacterial Sepsis
Gram-Negative Bacterial Sepsis
Other Pathogens
Hospitals
Pathology & Reference Laboratories
Others
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
Middle East and Africa
The major global players in the market include Thermo Fisher Scientific Inc., Bruker Corporation, Merck Millipore, Siemens Healthineers, Becton, Dickinson, and Company, Hoffmann-LA Roche Ltd, T2 Biosystems, Inc., Response Biomedical Corp., BioMerieux SA, and Immunexpress Inc. among others.
On April 18, 2023, Carle Illinois College of Medicine faculty member Rashid Bashir received marketing approval from the Food and Drug Administration for A new AI tool for sepsis diagnosis developed from research.
On November 27, 2023, Asep Medical Holdings Inc. secured patent approval in the US for its AI-based sepsis diagnostic technology, SepsetER.
To visualize the global Sepsis Diagnostic market segmentation based on Product, Technology, Diagnostic Method, Pathogen and End-User and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of Sepsis Diagnostic market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global Sepsis Diagnostic market report would provide approximately 53 tables, 47 figures and 176 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies